Alderson NL - Search Results

1

Role of lipids in chemical modification of proteins and development of complications in diabetes.

Januszewski AS, Alderson NL, Metz TO, Thorpe SR, Baynes JW. Januszewski AS, et al. Among authors: alderson nl. Biochem Soc Trans. 2003 Dec;31(Pt 6):1413-6. doi: 10.1042/bst0311413. Biochem Soc Trans. 2003. PMID: 14641077 Review.

2

Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.

Alderson NL, Chachich ME, Frizzell N, Canning P, Metz TO, Januszewski AS, Youssef NN, Stitt AW, Baynes JW, Thorpe SR. Alderson NL, et al. Diabetologia. 2004 Aug;47(8):1385-95. doi: 10.1007/s00125-004-1474-8. Epub 2004 Jul 28. Diabetologia. 2004. PMID: 15309289

3

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW. Degenhardt TP, et al. Among authors: alderson nl. Kidney Int. 2002 Mar;61(3):939-50. doi: 10.1046/j.1523-1755.2002.00207.x. Kidney Int. 2002. PMID: 11849448 Free article.

4

Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications.

Metz TO, Alderson NL, Chachich ME, Thorpe SR, Baynes JW. Metz TO, et al. Among authors: alderson nl. J Biol Chem. 2003 Oct 24;278(43):42012-9. doi: 10.1074/jbc.M304292200. Epub 2003 Aug 15. J Biol Chem. 2003. PMID: 12923193 Free article.

5

Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.

Metz TO, Alderson NL, Thorpe SR, Baynes JW. Metz TO, et al. Among authors: alderson nl. Arch Biochem Biophys. 2003 Nov 1;419(1):41-9. doi: 10.1016/j.abb.2003.08.021. Arch Biochem Biophys. 2003. PMID: 14568007 Review.

6

Chemical modification of muscle protein in diabetes.

Alt N, Carson JA, Alderson NL, Wang Y, Nagai R, Henle T, Thorpe SR, Baynes JW. Alt N, et al. Among authors: alderson nl. Arch Biochem Biophys. 2004 May 15;425(2):200-6. doi: 10.1016/j.abb.2004.03.012. Arch Biochem Biophys. 2004. PMID: 15111128

7

Chemical modification of proteins during peroxidation of phospholipids.

Januszewski AS, Alderson NL, Jenkins AJ, Thorpe SR, Baynes JW. Januszewski AS, et al. Among authors: alderson nl. J Lipid Res. 2005 Jul;46(7):1440-9. doi: 10.1194/jlr.M400442-JLR200. Epub 2005 Apr 1. J Lipid Res. 2005. PMID: 15805546 Free article.

8

S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate.

Alderson NL, Wang Y, Blatnik M, Frizzell N, Walla MD, Lyons TJ, Alt N, Carson JA, Nagai R, Thorpe SR, Baynes JW. Alderson NL, et al. Arch Biochem Biophys. 2006 Jun 1;450(1):1-8. doi: 10.1016/j.abb.2006.03.005. Epub 2006 Mar 22. Arch Biochem Biophys. 2006. PMID: 16624247

9

Simple non-invasive assessment of advanced glycation endproduct accumulation.

Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans ROB, Smit AJ. Meerwaldt R, et al. Among authors: alderson nl. Diabetologia. 2004 Jul;47(7):1324-1330. doi: 10.1007/s00125-004-1451-2. Epub 2004 Jul 9. Diabetologia. 2004. PMID: 15243705

10

The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.

Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR. Stitt A, et al. Among authors: alderson nl. Diabetes. 2002 Sep;51(9):2826-32. doi: 10.2337/diabetes.51.9.2826. Diabetes. 2002. PMID: 12196477

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters